Darzalex Faspro

Active Ingredient(s): Daratumumab + Hyaluronidase-fihj
FDA Approved: * May 1, 2020
Pharm Company: * JANSSEN BIOTECH
Category: Cancer

Daratumumab/hyaluronidase, sold under the brand name Darzalex Faspro, is a fixed-dose combination medication for the treatment of adults with newly diagnosed or relapsed/refractory multiple myeloma.[2][1][3] It is a combination of daratumumab and hyaluronidase.[1] It is administered via subcutaneous injection.[1] The most common adverse reaction using daratumumab/hyaluronidase as monotherapy is upper respiratory t... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Darzalex Faspro Subcutaneous Injection
NDC: 57894-503
Janssen Biotech, Inc.